377 related articles for article (PubMed ID: 12496436)
1. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
[TBL] [Abstract][Full Text] [Related]
2. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL
J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
Morris CB; Cheng E; Thanawastien A; Cárdenas-Freytag L; Clements JD
Vaccine; 2000 Mar; 18(18):1944-51. PubMed ID: 10699345
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
6. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions.
Hiroi T; Goto H; Someya K; Yanagita M; Honda M; Yamanaka N; Kiyono H
J Immunol; 2001 Nov; 167(10):5862-7. PubMed ID: 11698461
[TBL] [Abstract][Full Text] [Related]
7. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
8. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
[TBL] [Abstract][Full Text] [Related]
9. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.
Imaoka K; Miller CJ; Kubota M; McChesney MB; Lohman B; Yamamoto M; Fujihashi K; Someya K; Honda M; McGhee JR; Kiyono H
J Immunol; 1998 Dec; 161(11):5952-8. PubMed ID: 9834076
[TBL] [Abstract][Full Text] [Related]
10. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
[TBL] [Abstract][Full Text] [Related]
11. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
Vinner L; Nielsen HV; Bryder K; Corbet S; Nielsen C; Fomsgaard A
Vaccine; 1999 Apr; 17(17):2166-75. PubMed ID: 10367950
[TBL] [Abstract][Full Text] [Related]
12. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
[TBL] [Abstract][Full Text] [Related]
13. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
[TBL] [Abstract][Full Text] [Related]
14. Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system.
Kunisawa J; Nakanishi T; Takahashi I; Okudaira A; Tsutsumi Y; Katayama K; Nakagawa S; Kiyono H; Mayumi T
J Immunol; 2001 Aug; 167(3):1406-12. PubMed ID: 11466359
[TBL] [Abstract][Full Text] [Related]
15. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG.
Lowell GH; Kaminski RW; VanCott TC; Slike B; Kersey K; Zawoznik E; Loomis-Price L; Smith G; Redfield RR; Amselem S; Birx DL
J Infect Dis; 1997 Feb; 175(2):292-301. PubMed ID: 9203649
[TBL] [Abstract][Full Text] [Related]
16. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
17. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
[TBL] [Abstract][Full Text] [Related]
18. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses.
Kato H; Bukawa H; Hagiwara E; Xin KQ; Hamajima K; Kawamoto S; Sugiyama M; Sugiyama M; Noda E; Nishizaki M; Okuda K
Vaccine; 2000 Jan; 18(13):1151-60. PubMed ID: 10649615
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
Durrani Z; McInerney TL; McLain L; Jones T; Bellaby T; Brennan FR; Dimmock NJ
J Immunol Methods; 1998 Nov; 220(1-2):93-103. PubMed ID: 9839930
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
